Wall Street brokerages expect ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) to post earnings of ($0.43) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings of ($1.80) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 76.1%. The firm is scheduled to issue its next quarterly earnings results on Monday, December 10th.
On average, analysts expect that ESSA Pharma will report full year earnings of ($2.60) per share for the current year. For the next year, analysts expect that the business will report earnings of ($1.77) per share, with EPS estimates ranging from ($1.80) to ($1.74). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for ESSA Pharma.
ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its earnings results on Tuesday, August 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.24.
An institutional investor recently bought a new position in ESSA Pharma stock. DRW Securities LLC acquired a new position in shares of ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 33,857 shares of the company’s stock, valued at approximately $128,000. DRW Securities LLC owned about 0.59% of ESSA Pharma at the end of the most recent reporting period. 66.46% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ EPIX opened at $3.71 on Friday. The stock has a market capitalization of $17.33 million, a PE ratio of -0.46 and a beta of 1.61. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.33 and a current ratio of 5.33. ESSA Pharma has a 1 year low of $2.00 and a 1 year high of $7.40.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Recommended Story: What is the float in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.